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Summary
Several receptor tyrosine kinases require heparan sul-
fate proteoglycans (HSPGs) as coreceptors for effi-
cient signal transduction. We have studied the role
of HSPGs in the development of blood capillary struc-
tures from embryonic stem cells, a process strictly de-
pendent on signaling via vascular endothelial growth
factor receptor-2 (VEGFR-2). We show, by using chi-
meric cultures of embryonic stem cells defective in ei-
ther HS production or VEGFR-2 synthesis, that VEGF
signaling in endothelial cells is fully supported by HS
expressed in trans by adjacent perivascular smooth
muscle cells. Transactivation of VEGFR-2 leads to
prolonged and enhanced signal transduction due to
HS-dependent trapping of the active VEGFR-2 signal-
ing complex. Our data imply that direct signaling via
HSPG core proteins is dispensable for a functional
VEGF response in endothelial cells. We propose that
transactivation of tyrosine kinase receptors by HSPGs
constitutes a mechanism for crosstalk between adja-
cent cells.
Introduction
Heparan sulfate proteoglycans (HSPGs) are transmem-
brane, glycosylphosphatidylinositol-anchored or se-
creted proteins with covalently linked heparan sulfate
(HS) chains that modulate the activity of a large number
of secreted signaling molecules. HS is a linear, N- and
O-sulfated glycosaminoglycan expressing diverse sul-
fated epitopes that constitute binding sites for protein li-
gands. More than 100 proteins have been reported to
interact with the HS moiety of HSPGs, or with heparin,
a related but more highly sulfated polysaccharide pro-
duced and released only by connective tissue-type
mast cells (Bernfield et al., 1999; Esko and Selleck,
2002). HSPGs are present in high copy numbers on
cell surfaces, and expressed by most cells in mamma-
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plicated in many aspects of growth factor function, such
as in formation of higher order receptor complexes
(Yayon et al., 1991) and in growth factor transport and
gradient formation (Belenkaya et al., 2004; Han et al.,
2005; Kirkpatrick et al., 2004; Kreuger et al., 2004; The
et al., 1999). Several angiogenic growth factors, such
as vascular endothelial growth factor (VEGF)-A, fibro-
blast growth factor (FGF)-2, and platelet-derived growth
factor (PDGF)-BB, depend on HS/heparin for full biolog-
ical effect (Gitay-Goren et al., 1992; Rolny et al., 2002;
Yayon et al., 1991). Heparin can partially compensate
for the lack of HS expression in several tissue culture
models, presumably by serving as a scaffold that facili-
tates or stabilizes the interaction between growth fac-
tors and their receptors. Physiologically, however, hep-
arin and HS appear to have distinct and nonoverlapping
functions.
Binding of growth factors to HS/heparin is regulated
by differential sulfation of the polysaccharide backbone,
creating a multitude of protein binding domains
(Kreuger et al., 2005). The bifunctional enzymes of the
N-deacetylase/N-sulfotransferase (NDST) family cata-
lyze early steps in HS biosynthesis that are crucial for
proper HS sulfation (Grobe et al., 2002). There are four
vertebrate NDST isoforms, of which NDST1 and 2 dis-
play broad and overlapping tissue distribution. Gene in-
activation of murine NDST1 leads to a dramatic reduc-
tion in N- and O-sulfation of HS in most basement
membranes. The majority of NDST1-deficient embryos
survive until birth but die shortly thereafter in a condition
resembling respiratory distress syndrome (Fan et al.,
2000; Ringvall et al., 2000). Elimination of NDST2 expres-
sion is compatible with survival and fertility, but the mice
are unable to synthesize sulfated heparin (Forsberg
et al., 1999). Combined inactivation of the Ndst1 and 2
genes results in early embryonic lethality (K.H. and L.K.,
unpublished data). HS produced by Ndst1/22/2cells is
devoid of both N-sulfate and 2-O-sulfate groups, while
a low level of 6-O-sulfation remains (Holmborn et al.,
2004).
During vascular development, blood vessels are
formed through in situ differentiation of mesodermal
precursor cells denoted angioblasts into endothelial
cells (Flamme et al., 1997). Maturation of the vasculature
involves pruning of vessels and eventually formation of
capillaries from preexisting vessels, a process known
as angiogenesis. Stabilization of the newly formed ves-
sel requires production of a specialized basement mem-
brane and attraction of supporting perivascular smooth
muscle cells, pericytes. Inactivation of the gene for
VEGF-A or one of its receptors, VEGFR-2 (alternatively
denoted Flk-1/KDR to indicate murine or human spe-
cies, respectively), severely impairs vasculogenesis
and hematopoiesis in the embryo, leading to embryonic
death (Ferrara et al., 1996; Shalaby et al., 1995). VEGF-A/
VEGFR-2 are critical also in physiological vessel mainte-
nance in the adult (Kamba et al., 2006). Furthermore,
most, if not all, tumors produce VEGF-A, leading to
excessive and deregulated pathological angiogenesis.
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spliced exons (for a review, see Olsson et al., 2006)
that give rise to protein isoforms with different biological
properties. The shortest isoform, VEGF-A121, lacks the
HS binding domain and is freely diffusible. The most
commonly expressed isoform, VEGF-A165, includes
the HS binding domain and is retained at the cell surface
or in the extracellular matrix (Leung et al., 1989; Park
et al., 1993; Tischer et al., 1989).
We show here through coculture of stem cells defec-
tive in either HSPG or VEGFR-2 production that HSPGs
expressed in trans relative to VEGFRs support formation
of functional VEGFR complexes with enhanced signal-
ing properties in response to VEGF-A165 but not
VEGF-A121. This represents a mechanism for HS-de-
pendent transactivation regulating signaling and turn-
over of tyrosine kinase receptors.
Results and Discussion
The objective of this study was to define the role of HS in
VEGFR-2 signaling and the subsequent development of
endothelial cells and capillary structures. As a model, we
used clusters of differentiating mouse embryonic stem
(ES) cells, designated embryoid bodies, which faithfully
mimic early steps of vascular development (Magnusson
et al., 2004; Vittet et al., 1996). Wild-type embryoid bod-
ies responded to VEGF-A165 with formation of a periph-
eral vascular plexus consisting of sprouting capillary-
like structures (Figure 1A). In contrast, embryonic stem
cells established from Ndst1/22/2 blastocysts failed to
respond to VEGF-A165 (Figure 1A). The lack of response
of the Ndst1/22/2 embryoid bodies is in agreement with
the fact that NDST enzymes catalyze early steps in the
sulfation of HS/heparin, and that VEGF-A165 is a heparin
binding growth factor (Ruhrberg et al., 2002). Inclusion
of heparin or purified HS in the embryoid body cultures
over a wide range of concentrations and for different
time periods in the presence of VEGF-A165 (Figure 1A,
and data not shown) consistently failed to support vas-
cular development in the Ndst1/22/2 embryoid bodies.
Because purified and endogenous HS might differ sig-
nificantly in degree and pattern of sulfation, we investi-
gated the potential contribution of endogenously pro-
duced, soluble HS in VEGFR-2 signaling. This was
accomplished through transwell coculture of HS-pro-
ducing vegfr-22/2 embryoid bodies withNdst1/22/2 em-
bryoid bodies placed in tissue culture inserts (see
Figure 1B for experimental setup). The vegfr-22/2 cells
secreted readily detectable levels of HS that diffused
into the upper chamber (Figure 1C, and data not shown).
Despite the presence of soluble wild-type HS in the cul-
ture medium, inclusion of VEGF-A165 failed to induce
vessel formation in the Ndst1/22/2 embryoid bodies,
compared with control wild-type embryoid bodies that
responded to VEGF-A165 with formation of a richly
branched endothelial cell plexus (Figure 1D). Moreover,
conditioned medium from vegfr-22/2 cultures was trans-
ferred onto Ndst1/22/2 embryoid bodies, which also
failed to support vascular development (data not
shown). Taken together, these results show that attenu-
ation of NDST1/2 expression interrupts VEGF-A165-
dependent vascular development, and this process is
not rescued by soluble HS/heparin.A well-established nitrocellulose filter binding assay
(Kreuger et al., 2003) was employed to investigate the
binding of HS/heparin to VEGF. Figure 1E shows
that VEGF-A165, but not VEGF-A121, bound heparin
although not to the same extent as an equimolar concen-
tration of the positive control, FGF-2. Moreover, HS puri-
fied from vegfr-22/2 stem cells, but not from Ndst1/22/2
stem cells, efficiently bound VEGF-A165 (Figure 1F).
To test whether the Ndst1/22/2 embryoid bodies
could be rescued by cell-associated HS, we designed a
chimeric stem cell culture model whereNdst1/22/2 stem
cells were mixed at different ratios with vegfr-22/2 stem
cells and thereafter allowed to differentiate in response
to VEGF-A165. Importantly, embryoid bodies derived
exclusively from either Ndst1/22/2 or vegfr-22/2 stem
cells failed to undergo vascular development (Figures
1A and 2). In contrast, a striking rescue with endothelial
cell differentiation and vascular plexus formation was
seen in VEGF-A165-treated embryoid bodies composed
of a mixture of Ndst1/22/2 and vegfr-22/2 stem cells at
ratios of 1:9, 1:1, and 9:1 (Ndst1/22/2:vegfr-22/2; see
Figure 2).
Alteration in HS production or sulfation can be ex-
pected to have global effects on growth factor signaling.
Consequently, the recorded lack of vascular develop-
ment by Ndst1/22/2 embryoid bodies could be due to
a partial or complete arrest in mesoderm formation.
We therefore analyzed transcript levels of genes ex-
pressed within the mesoderm (vegfr-2, pdgfr-b, and bra-
chyury) and the endoderm (afp and gata-4) by PCR from
reverse transcripts prepared from wild-type,Ndst1/22/2,
vegfr-22/2, or chimeric 9:1 (Ndst1/22/2:vegfr-22/2; here-
after denoted chimeras) embryoid bodies, at different
stages of differentiation. Transcripts of vegfr-2 and
pdgfr-bwere detected at day 4 and 8 in embryoid bodies
derived from Ndst1/22/2, wild-type, and chimeric cul-
tures and the transcripts persisted in the wild-type and
chimeric bodies until day 12. As expected, there were
no vegfr-2 transcripts expressed in the vegfr-22/2 stem
cells (see Table 1; based on Figure S1A in the Supple-
mental Data available with this article online). brachyury
transcripts were absent in theNdst1/22/2 cultures under
the conditions used here, whereas the kinetics of expres-
sion of brachyury in the chimeras followed that of
wild-type, only at lower levels. The expression of the
endoderm-derived a-fetoprotein (afp) was comparable
in chimeras and wild-type but delayed inNdst1/22/2 cul-
tures. gata-4 mRNA was undetectable in Ndst1/22/2
stem cells as well as in the chimeras. These results indi-
cate defects in mesodermal and endodermal differentia-
tion in Ndst1/22/2 stem cells and partial genotypic
rescue in the chimeric embryoid bodies, allowing for
a complete rescue of vascular development (Figure 2).
To analyze the potential genotypic drift over time in
the chimeric embryoid bodies, we studied expression
of Ndst2 by real-time PCR (Figure S1B). Because
Ndst2 was absent in the Ndst1/22/2 cells, this analysis
reflects an estimate of the vegfr-22/2 pool within the chi-
meras. Although 90% of the cells lacked Ndst2 at day 0,
the expression at day 4, 8, and 12 was 62%, 63%, and
77% of that in vegfr-22/2, respectively, indicating a ge-
netic drift toward the vegfr-22/2 genotype. In chimeras
treated with VEGF, however, staining revealed an in-
creased pool of VEGFR-2-positive cells, illustrating an
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627Figure 1. Both Soluble HS and Heparin Fail to Rescue Endothelial Cell Development in Ndst1/22/2 Embryoid Bodies
(A) Wild-type (Wt) but not Ndst1/22/2 embryoid bodies develop vascular structures. Embryoid bodies formed from wild-type or Ndst1/22/2 em-
bryonic stem cells were seeded on glass slides in the absence (basal) or presence of VEGF-A165 (30 ng/ml) and heparin (100 ng/ml). At day 10,
the bodies were fixed and stained for expression of CD31. The scale bar represents 1 mm. Inset shows higher magnification of the vascular
plexus. The scale bar represents 100 mm.
(B) Experimental setup for transwell experiments.
(C) Embryoid bodies secrete HS into the medium. Eight-day-old embryoid bodies were metabolically labeled with [35S]sulfate overnight. Radio-
labeled glycosaminoglycans (GAGs) were isolated from the medium and separated on Sephadex G50 before (open box) or after (triangles) HNO2
digestion to degrade HS. The distribution of radioactivity before and after digestion shows that 46% of total GAGs retrieved from the medium
were HS.
(D) Soluble HS does not rescue vascular development in Ndst1/22/2 ES cells. Ndst1/22/2 ES cells were differentiated in conditioned medium
from vegfr-22/2 cultures until day 4 and further cultured in tissue culture inserts with vegfr-22/2 embryoid bodies, secreting HS, in the bottom
of the well. The bodies were stained for expression of CD31 after 6 days of differentiation in the transwell setup. Arrowheads indicate capillary
structures. The scale bar represents 100 mm.
(E) VEGF-A165 and FGF-2, but not VEGF-A121, bind to heparin. The bars indicate standard deviation.
(F) VEGF-A165 binds HS isolated from vegfr-22/2 embryoid bodies, but not HS purified from Ndst1/22/2 embryoid bodies. The graph illustrates
the mean of two measuring points (* and + indicate highest and lowest value, respectively).expansion of Ndst1/22/2-derived endothelial cells (Fig-
ure 3). These data demonstrate the plasticity of the
model employed, allowing expansion of different sub-
populations of cell lineages depending on the context.
A model of invasive angiogenesis was employed to
identify VEGFR-2- and HS-expressing cell types con-
tributing to the development of vascular structures in
the chimeric embryoid bodies. For this purpose, embry-
oid bodies were cultured in three-dimensional collagen I
gels and stimulated with VEGF-A165 to induce out-
growth of capillary-like structures into the surroundingmatrix. Neither Ndst1/22/2 nor vegfr-22/2 embryoid
bodies responded to VEGF-A165 (Figure 3A), whereas
wild-type as well as chimeric cultures responded vig-
orously by extending sprouts of endothelial cells
(CD31- and VEGFR-2-double positive; Figures 3B and
3C) covered with perivascular smooth muscle cells (ver-
ified as a smooth muscle actin [aSMA]-positive; Fig-
ure 3D), hereafter denoted pericytes. We conclude that
the Ndst1/22/2 stem cells serve as the source for
VEGFR-2-expressing endothelial cells in the chimeric
cultures.
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628Figure 2. Chimeras of vegfr-22/2 and Ndst1/22/2 ES Cells Allow Rescue of Vascular Development in Response to VEGF-A165
Ndst1/22/2 and vegfr-22/2 embryonic stem cells were mixed at different ratios (Ndst1/22/2: vegfr-22/2 at 1:9, 1:1, or 9:1 ratios as indicated) to
create chimeric embryoid bodies, which were cultured in the presence or absence of VEGF-A165. The bodies were stained for expression of
CD31 on day 10 (shown in red). In parallel, bodies were stained with Hoechst to visualize nuclei (lower panel). Arrow indicates CD31-positive
capillary plexus. The scale bar represents 1 mm.Cells expressing wild-type HS were identified with
a monoclonal antibody, HepSS-1, which recognizes
highly sulfated epitopes in wild-type HS. HepSS-1
showed reactivity for both endothelial cells and peri-
cytes in angiogenic sprouts in the wild-type embryoid
bodies (Figure 4A, left panel). However, in the chimeric
cultures, HepSS-1 reactivity was restricted to the peri-
cytes (Figure 4A, right panel). Hence, sulfated and
functional HS in the VEGF-A165-induced sprouts was
expressed only by pericytes derived from vegfr-22/2
stem cells (see Figure S2 for costaining for VEGFR-2,
aSMA, and HS). This finding suggests that functional
VEGFR-2 activation is supported by HSPGs in trans.The critical role of HS for the ability of the chimeric em-
bryoid bodies to respond to VEGF-A165 in the sprouting
assay was further demonstrated by enzymatic digestion
of HS with heparinase I–III. This treatment resulted in
a marked decrease in the number of angiogenic sprouts
(Figures 4B and 4C). In accordance with this, exposure
of chimeric cultures to VEGF-A121, which lacks the HS
binding domain (see Figure 1E), failed to induce angio-
genic sprouting (Figures 4D and 4E). Taken together,
these data demonstrate an essential role of HS in
VEGF-A165/VEGFR-2 complex formation and signaling.
Chimeric embryoid bodies created by mixing Ndst1/
22/2 and vegfr-22/2 ES cells at a 9:1 ratio (i.e., onlyTable 1. mRNA Levels of Germ Layer Marker Genes Measured by PCR on Reverse Transcripts Prepared from the Different Embryoid Body
Cultures at Day 4, 8, and 12 of Development
Mesodermal Transcriptsa Endodermal Transcriptsa
Days of Culture Genotype vegfr-2 pdgfr-b brachyury afp Gata-4
4 Ndst1/22/2 + + + + + — — —
Wt + + + + + + + + + + + + + + + + +
9:1 + + + + + + + —
vegfr-22/2 — + + + + + + + + + +
8 Ndst1/22/2 + + + + + + — — —
Wt + + + + + + + + + + + + + + + + + +
9:1 + + + + + + + + + + + —
vegfr-22/2 — + + + + + + + + + + + + +
12 Ndst1/22/2 — + + + — + —
Wt + + + + + + + + + + + + + + + +
9:1 + + + + + + + — + + + + —
vegfr-22/2 — + + + + + + + + + + + + + +
a Transcript levels are indicated as absent (2) or from low (+) to high (+ + + +) as estimated from PCR band intensities (see Figure S1A).
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629Figure 3. Chimeric Embryoid Bodies Produce Normal Sprouts in 3D Collagen Gels
(A and B)Ndst1/22/2, vegfr-22/2, chimeric, and wild-type (Wt) embryoid bodies were placed in 3D collagen gels at day 4 and cultured with VEGF-
A165 until day 10. The embryoid bodies were stained (whole-mount) for expression of CD31 (red) and aSMA (green).
(A) The VEGFR-2- and NDST1/2-deficient embryoid bodies failed to respond to VEGF-A165.
(B) In contrast, both wild-type and chimeric embryoid bodies displayed a halo of CD31-positive sprouts, surrounded by aSMA-positive cells,
which invaded the collagen gel (arrowheads). The scale bars represent 300 mm.
(C) Endothelial cells in the chimeras coexpressed CD31 and VEGFR-2, hence they were derived from the Ndst1/22/2 cells expressing VEGFR-2.
The scale bar represents 100 mm.
(D) Surrounding cells were negative for these markers but positive for aSMA (arrowheads).10% HS-producing vegfr-22/2ES cells; see Figure 2) still
responded vigorously to VEGF-A165 treatment. This
motivated a closer examination of the properties of
VEGFR-2 activation and turnover in the chimeric embry-
oid bodies. As shown in Table 1, vegfr-2 transcripts were
detected in differentiating embryoid bodies derived
from Ndst1/22/2, chimeric, and wild-type cultures, but
not in vegfr-22/2 embryoid bodies. In agreement, immu-
noblotting showed two bands (see Figure S3A), corre-
sponding in size to the described VEGFR-2 forms differ-
ing in extent of N-linked glycosylation (Takahashi and
Shibuya, 1997), that were expressed at lower levels in
the Ndst1/22/2 and the chimeric cultures than in the
wild-type. It is noteworthy that the lower expression
level of VEGFR-2 in the chimeras compared to wild-
type embryoid bodies did not reflect a reduced number
of endothelial cells, as suggested by both immunostain-
ing (Figure 3B) and immunoblotting (see Figure 5D) for
the endothelial cell marker CD31. The slightly reduced
mobility of VEGFR-2 in the chimeric cultures was at least
in part due to changes in glycosylation, as judged from
digestion with N-glycosidase F (data not shown). Treat-
ment of the wild-type embryoid bodies with VEGF-A165
induced activation of VEGFR-2 as indicated by tyrosinephosphorylation of the receptor (Figure 5A), but with
slower kinetics than that previously noticed in serum-
starved endothelial cell monolayer cultures (Singh
et al., 2005). Studies in such models have shown that re-
ceptor tyrosine kinases become rapidly internalized in
response to ligand binding; concomitantly, there is an
increased rate of protein synthesis and transport of
newly synthesized receptors to the cell surface (Eriks-
son et al., 1991; Kremer et al., 1997). The chimeric cul-
tures also responded to VEGF-A165 with tyrosine phos-
phorylation of the receptor. Remarkably, VEGFR-2
protein levels and receptor tyrosine phosphorylation
persisted in the chimeras and increased over the first 2
hr (Figure 5A; see quantification in Figure 5B). In con-
trast, the expression of VEGFR-2 protein in the wild-
type embryoid bodies decreased after 1–3 hr of stimula-
tion, followed by a restoration to basal levels (see
Figure S3B). Analysis over longer time periods showed
that phosphorylated VEGFR-2 (in relation to VEGFR-2
protein) increased in the chimeras followed by a gradual
decrease to the basal level by 24 hr (Figure 5C). In the
wild-type embryoid bodies, a much smaller fraction of
receptors became tyrosine phosphorylated in relation to
the total VEGFR-2 pool. Consistently, we observed at
Developmental Cell
630Figure 4. Pericytes Present HS in trans to Endothelial Cells in Angiogenic Sprouts in the Chimeras
(A) Embryoid bodies from wild-type (Wt; left) stem cells or from chimeric (right) cultures were seeded in 3D collagen gels in the presence of VEGF-
A165. Immunofluorescent staining showed colocalization of CD31 (green) and HS (red; visualized by staining with the HepSS-1 antibody) on en-
dothelial cells in the wild-type embryoid bodies (arrows in the wild-type panel). In the chimeric cultures, HS was localized on pericytes (arrow)
adjacent to the CD31-positive endothelial cells (arrowhead), in agreement with the fact that wild-type HS was produced only by cells derived from
vegfr-22/2 ES cells. Hoechst staining (blue) was performed to visualize nuclei. The scale bar represents 50 mm. For VEGFR-2, HS, and aSMA
costaining, see Figure S2.
(B) Digestion of HS by heparinase I–III reduced the VEGF-induced response. The scale bar represents 200 mm.
(C) Quantification of CD31-positive structures in chimeric embryoid bodies (in Figure 4B) with or without HS digestion. The bars indicate standard
deviation.
(D) The nonheparin binding VEGF isoform 121 did not induce endothelial cell sprouting.
(E) Quantification of the fraction of embryoid bodies positive for sprouting in (D).least a 10-fold higher fraction of activated receptors
in the chimeras compared to wild-type. VEGFR-2 ex-
pressed in the Ndst1/22/2 embryoid bodies failed to re-
spond to VEGF-A165 (data not shown) due to the HS
deficiency, and were not further analyzed with regard
to signaling or turnover.
In a pulse-chase analysis, cultures were exposed to
VEGF-A165 for a limited period of time, followed by
washing and continued culture in complete medium
(Figure 5D). Thereby, the induction and clearance of
a limited pool of tyrosine-phosphorylated VEGFR-2
could be followed over time, without continuous inclu-
sion of newly activated receptors as in Figures 5A–5C
(where cultures were exposed to growth factor through-
out the experiment). As seen in Figure 5E, the level of
phospho-VEGFR-2 increased dramatically (about 20-fold) in the chimeric embryoid bodies, and remained
for several hours. In contrast, the wild-type cultures dis-
played a 2-fold, transient increase in phosphorylated
VEGFR-2. The moderate amplitude in VEGFR-2 phos-
phorylation in the wild-type compared to chimeras
might in part be a consequence of the higher basal
phosphorylation in the wild-type setting (Figure 5D).
Moreover, in the wild-type, HS may interact with the
receptor complex both in cis and in trans, which com-
plicates a direct comparison with the ‘‘in trans only’’
chimeric condition. However, we conclude that VEGF-
A165-induced signaling is potentiated by HSPGs pre-
sented in trans to the receptor and that HS-dependent
trapping of VEGFR-2 results in an accumulation of re-
ceptors, instead of downregulation as in the wild-type
situation, with prolonged activation as a consequence.
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(A) Chimeric and wild-type embryoid bodies (day 11) were exposed to VEGF-A165 and harvested at different time points. VEGFR-2 protein was
immunoprecipitated (IP), followed by immunoblotting (IB) for phosphotyrosine (pY), for VEGFR-2, or as a control for equal loading, for laminB.
The slightly reduced mobility of VEGFR-2 in the chimeric cultures is at least in part due to changes in glycosylation, as judged from digestion with
N-glycosidase F (data not shown).
(B) Quantification of VEGFR-2 expression in (A) shows that levels increased over time in the chimeras.
(C) Quantification of tyrosine-phosphorylated VEGFRs relative to total VEGFR-2 protein following VEGF-A165 stimulation for 0, 1, 3, 6, and 24 hr
(the immunoblot used for quantification is shown in Figure S3B).
(D) Clearance of VEGFR-2 in embryoid bodies pulsed with VEGF-A165 for 30 min followed by washing and ‘‘chase’’ in full growth medium. Cul-
tures harvested at different time points were analyzed by IP/IB for phospho-VEGFR-2 and total VEGFR-2 protein. Equal loading was controlled
by blotting for actin. Blotting for CD31, a vascular marker, shows similar expression levels in different cultures.
(E) Quantification of phosphorylated receptors in (D) illustrating differential signaling kinetics in wild-type and chimeric embryoid bodies.We suggest that transactivation of VEGFR-2 by HSPGs
presented by pericytes or perivascular cell types, alter-
natively by the extracellular matrix/basement mem-
brane, efficiently captures receptor complexes at the
cell surface. Thereby, internalization and degradation
of phosphorylated receptors is delayed, allowing effi-
cient utilization of activated receptors in transduction
of biological responses (Figure 6).
The sulfation of HS is subject to strict developmental
control in a tissue- and age-dependent manner (Feyzi
et al., 1998). Our data support the notion that the sulfa-
tion of HSPGs is crucial for the regulation of cell differen-
tiation in a physiological setting. We show that VEGF-
A165 readily interacts with wild-type HS, but not with
undersulfated HS derived from Ndst1/22/2 stem cells,
and that sprouting angiogenesis is sensitive to HS deg-
radation. VEGF-A121, which is unable to bind heparin/
HS, failed to induce angiogenic sprouting (cf. Figure 4D).
In agreement with our data, path finding of vascular
sprouts in the developing retina is impaired in mice ex-
pressing only the VEGF-A120 isoform (corresponding
to the human VEGF-A121), pointing to a role for HSPGs
in guidance of vascular sprouts by modulating VEGF
gradient formation (Ruhrberg et al., 2002). It is conceiv-able that part of the rescue of blood endothelial cell dif-
ferentiation seen here in chimeric cultures is due to a re-
stored VEGF-A165 gradient formation. Interestingly, not
only VEGF-A165, but also VEGFR-2, displays an HS/
heparin binding motif (Dougher et al., 1997). In addition,
coreceptors for VEGFs of the neuropilin family interact
with HS/heparin (Mamluk et al., 2002). Thus, all compo-
nents in the putative VEGF-A165/VEGFR-2/neuropilin
signaling complex have the capacity to bind directly to
HS. Our data suggest that the stability and turnover of
VEGFR-2 is modulated by HSPGs. The delay in clear-
ance of VEGFR-2 that we observed in the chimeric cul-
tures is reminiscent of data on reduced FGFR internali-
zation in the presence of N-cadherin, leading to
increased FGFR stability and enhanced biological re-
sponses (Suyama et al., 2002). The half-life of the active
signaling complex may be regulated not only by the rate
of internalization but also by decreasing the off-rate of
the ligand as described for FGF/heparin/FGFR com-
plexes (Ibrahimi et al., 2004). The prolonged half-life
may in turn lead to an enhanced or altered pattern of ty-
rosine phosphorylation. In accordance, we have previ-
ously shown that inclusion of heparin is a prerequisite
for FGF-2-induced phosphorylation of the C-terminal
Developmental Cell
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membrane domain tyrosine residue 463 is phosphory-
lated both in the absence and presence of heparin
(Lundin et al., 2003). In vivo, differential expression of
HSPGs as well as temporal and spatial regulation of dis-
tinct protein binding HS epitopes may play a major role
in regulating signaling, not only by ligand binding, but
also as shown here, by modulating receptor turnover.
As a consequence of the experimental setup, we can
infer that direct signaling of the HS-bearing core protein
is dispensable for endothelial cell development, as only
properly sulfated and thus functional HSPG core pro-
teins exist in trans on pericytes, and not in endothelial
cells. Pericytes serve an important role in stabilization
and maturation of the vasculature; dissociation of peri-
cytes leads to endothelial cell apoptosis and vessel re-
gression. The molecular mechanisms in the close inter-
play between pericytes and endothelial cells resulting in
vessel survival are still poorly understood (Armulik et al.,
2005). It is possible that pericyte/endothelial cell trans-
communication involving efficient HS-dependent pre-
sentation of growth factors such as VEGF-A165 is criti-
cal in vessel stability.
It is noteworthy that the NDST1/2 deficiency most
likely hampered general development by affecting mul-
tiple HS-dependent processes, in addition to VEGF-
dependent ones. This is indicated by the delayed and
apparently defective endoderm development in the
Ndst1/22/2 ES cells (Table 1). Whether endoderm-
derived inductive signals are required for proper vascu-
logenesis such as in formation of vascular tubes is dis-
puted (Jin et al., 2005; Pardanaud et al., 1996; Vokes
and Krieg, 2002). The rescue of the Ndst1/22/2 pheno-
type by vegfr-22/2 ES cells may therefore have been
exerted on more than one level, by supplying normal en-
doderm to facilitate general development and by sup-
plying cell surface HS to allow signal transduction
through the VEGF/VEGFR-2 complex.
Figure 6. Model for Transactivation of VEGFR-2 by HS
(A) In the wild-type situation, the VEGFR-2 (blue) and VEGF (light red)
complex is bound to HS (green line) provided by the endothelial cell
itself.
(B) In the chimeras, where the VEGFR-2-positive endothelial cells
lack functional HS, the receptor-ligand complex is stabilized by HS
provided in trans, leading to trapping of the signaling VEGFR com-
plex at the cell surface and delayed internalization and degradation
of activated VEGFRs. Stabilization of the active signaling complex
may preserve and even enhance receptor phosphorylation (indi-
cated by P).In conclusion, we propose a mechanism whereby
HSPGs in trans may regulate VEGFR-2 signaling. This
finding has two major implications: first, it demonstrates
an intrinsic robustness of the VEGFR signaling pathway,
such that local, cell-autonomous deficiencies in HS pro-
duction can be fully rescued by adjacent cells. We note
that several studies have shown that adjacent cell
populations differ significantly with regard to expression
of HS epitopes, providing an in vivo context for such
transactivation (Dennissen et al., 2002). Second, our
findings demonstrate that transactivation via HSPGs
may be an additional avenue for crosstalk between adja-
cent cells. The general consequences of such crosstalk
for other HSPG-dependent tyrosine kinase receptors,
such as the FGF and PDGF receptors, require further
investigation.
Experimental Procedures
Embryonic Stem Cells
Murine 129 SvJ, R1 wild-type and vegfr-22/2 embryonic stem cells
(Shalaby et al., 1995) were kind gifts of Dr. Andras Nagy and Dr. Ja-
net Rossant, Samuel Lunenfeld Research Institute, Mount Sinai Hos-
pital, Toronto, Canada, respectively. The Ndst1/22/2 ES cells were
established as described by Holmborn et al. (2004).
Embryoid Bodies
ES cell clones were cultured in Dulbecco’s modified Eagle’s
medium/glutamax (Invitrogen), 25 mM HEPES, 1.2 mM sodium pyru-
vate, 19 mM monothioglycerol (Sigma), 15% fetal bovine serum, and
1000 units/ml leukemia inhibitory factor (LIF). At day 0, 1200
cells were aggregated in hanging drops (20 ml) without LIF, in the
presence or absence of 0.79 nM human recombinant VEGF-A165
(PeproTech) or VEGF-A121 (R&D), with or without 1, 10, or 100 ng/
ml heparin (Inolex Pharmaceutical Division) or 1, 10, 100, or 1000
ng/ml HS from pig intestinal mucosa (a gift from G. van Dedem, Dio-
synth, The Netherlands). Chimeric cultures of Ndst1/22/2 and vegfr-
22/2 ES cells were established at 1:9, 1:1, or 9:1 ratios. At day 4, the
embryoid bodies were placed in 8-well glass culture slides (BD Fal-
con) or in a collagen I suspension composed of Ham’s F12 medium
(Promocell), 6.26 mM NaOH, 20 mM HEPES, 0.117% NaHCO3, 1%
glutamax I (GIBCO), and 1.5 mg/ml collagen I (Cohesion). Medium
with or without growth factors was changed at day 8.
Immunostaining of Embryoid Bodies
At day 10, embryoid bodies on glass slides were processed for
whole-mount immunohistochemical staining as described previ-
ously (Magnusson et al., 2004). Embryoid bodies in collagen gels
were fixed in 4% p-formaldehyde in phosphate-buffered saline
(PBS), blocked, and permeabilized in 3% bovine serum albumin
(BSA), 0.2% Triton X-100 in PBS, followed by sequential overnight
incubations with primary and secondary antibodies. Hoechst
33342 was used to visualize the nuclei. The samples were analyzed
in either a Nikon Eclipse E1000 microscope with a Nikon Eclipse
DXM 1200 camera (Nikon) or an LSM 510 META confocal micro-
scope (Carl Zeiss). The following primary antibodies were used: rat
anti-mouse CD31 antibody (PharMingen), fluorescein isothiocya-
nate-conjugated mouse monoclonal anti-a smooth muscle actin
antibody, goat anti-mouse VEGFR-2 (R&D), rabbit anti-VEGFR-2
(Cell Signaling), and IgM mouse anti-mouse HepSS-1 antibody
(Seikagaku). Secondary antibodies were: Alexa 568 goat anti-rat
IgG, Alexa 488 goat anti-rat IgG, Alexa 555 donkey anti-goat IgG
or Alexa 555 goat anti-mouse IgM (Molecular Probes), Cy5 donkey
anti-rabbit IgG (Jackson ImmunoResearch), biotinylated goat anti-
rat IgG antibody, and horseradish peroxidase-conjugated streptavi-
din (Vector).
Transwell Cultures
From day 0 to day 4, Ndst1/22/2 ES cells were allowed to differenti-
ate in hanging drops with conditioned medium from wild-type em-
bryoid bodies. At day 4, the bodies were put individually in 24-well
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633cell culture inserts with 1 mm pore size membranes (BD Falcon). To
condition the medium in the insert cultures, vegfr-22/2 embryoid
bodies were seeded in the bottom of the wells 2 days prior to seed-
ing of Ndst1/22/2 bodies in the inserts. The Ndst1/22/2 bodies in the
inserts were cultured for 6 days after seeding. For experimental
setup, see Figure 1B.
Characterization of 35S-Labeled Glycosaminoglycans
Embryoid bodies cultured for 8 days were metabolically labeled for
22 hr with 330 mCi of [35S]sulfate in 5.5 ml of culture medium. After
incubation, 35S-labeled glycosaminoglycans were isolated from
the medium as previously described (Holmborn et al., 2004). After
treatment with 0.5 M NaOH for 18 hr at 4ºC followed by neutraliza-
tion, the labeled glycosaminoglycans were analyzed by gel chroma-
tography on Sephadex G50 superfine (0.53 100 cm) before and after
deamination with HNO2 at pH 1.5. This treatment results in cleavage
of HS at N-sulfated GlcN residues but leaves chondroitin sulfate
intact. The column was eluted in 0.2 M NH4HCO3 and fractions of
0.5 ml were collected and analyzed for 35S radioactivity.
Binding Assay
3H-labeled HS was isolated from Ndst1/22/2 and vegfr-22/2 embry-
oid bodies after metabolic labeling with [3H]glucosamine (33 mCi/ml)
for 24 hr as previously described (Holmborn et al., 2004). 3H-heparin
was a kind gift from Dr. Dorothe Spillmann, Uppsala University, Swe-
den. The binding of radiolabeled heparin/HS to VEGF-A121 and -165
and FGF-2 was analyzed with the nitrocellulose (NC) filter binding
assay, as described by Kreuger et al. (2003). Briefly, the different
growth factors were incubated with radiolabeled saccharide (7,000
cpm of [3H]heparin with 26 nmol growth factor, or 10,000 cpm of
[3H]HS with 130 nmol growth factor) in 50 ml PBS at room tempera-
ture for 15 min. The mixture was then rapidly passed through an
NC filter, where proteins and protein-bound saccharides bind to
the filter whereas free saccharides pass through. NC filters together
with protein-bound [3H]HS or [3H]heparin were analyzed for radioac-
tivity by scintillation counting.
Heparinase Digestion
Embryoid bodies were cultured in collagen with VEGF-A165 (30 ng/
ml). At day 6, a mixture of heparinase-I, -II, and -III (IBEX Pharmaceu-
ticals) was added to the cultures at a final concentration of 3.4 mU/
ml for each enzyme. This addition was repeated after 18 hr and 24 hr.
At day 8, fresh medium was supplied with addition of another 3.4
mU/ml heparinase I–III followed by one final addition of fresh
enzymes 24 hr later. Embryoid bodies were fixed at day 10 and
stained for CD31, as described above. Total area of positive struc-
tures in a total of 18 embryoid bodies per condition was quantified
with image analysis. Error bars represent standard deviation of the
mean.
Reverse Transcription Polymerase Chain Reaction
Total RNA was prepared from wild-type, Ndst1/22/2, chimeric, and
vegfr-22/2 embryoid bodies cultured in tissue culture dishes for 4,
8, and 12 days, by using an RNeasy mini kit (Qiagen). Samples
were DNase I treated (Qiagen) and RNA levels were determined by
spectrophotometry. One microgram of RNA from each condition
was used for reverse transcription (Upstate Biochemicals) to create
cDNA. The condition for the cDNA synthesis was 37ºC for 1 hr and
95ºC for 5 min. Primers were designed by using PrimerExpress
1.5a (Applied Biosystems) and synthesized by Invitrogen. The PCR
conditions were 95ºC for 10 min, (95ºC, 15 s/60ºC, 60 s)3 35 cycles.
The primer pairs used were: 50-CACTATTGGCAACGAGCGG-30, 50-
GACAGAGGCGATGAATGGTG-30 for vegfr-2, 50-GTGGTGAACTTC
CAATGGACG-30, 50-GTCTGTCACTGGCTCCACCAG-30 for pdgfr-b,
50-TAAGGAACCACCGGTCATCG-30, 50-TTGTCCGCATAGGTTGGA
GAG-30 for brachyury, 50-ACCCCTTCATGTATGCCCC-30, 50-GCAT
GCCAGAACGACCTTG-30 for a-fetoprotein, 50-AGCTCCATGTCC
CAGACTTCA-30, 50-AGCAGACAGCACTGGATGGAT-30 for Gata-4,
and 50-CACTATTGGCAACGAGCGG-30, 50-TCCATACCCAAGAAG
GAAGGC-30 for b-actin. In the analysis of Ndst2 mRNA levels,
primers were: 50-TGGACCGGTACTGTGTGGAG-30, 50-GGGCTCGG
AAAAAGCCA-30. Real-time PCR with SYBR Green PCR master mix
was run and detected in an ABI Prism 7700 instrument (Applied Bio-
systems). The expression levels were normalized to b-actin.Immunoblotting
Embryoid bodies were seeded in complete medium in tissue culture
dishes at day 4. At day 11, the cultures were stimulated for 0, 15, 30,
60, 90, or 120 min with VEGF-A165 at 100 ng/ml in complete medium.
For the pulse-chase analysis, embryoid bodies were pulsed with
VEGF-A165 for 30 min at 37ºC followed by extensive washes and
thereafter ‘‘chased’’ in full growth medium. The cells were lysed in
20 mM Tris HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1% NP40, 2
mM EDTA, 500 mM Na3VO4, 1% aprotinin, 10 mg/ml leupeptin, and
1 mM phenylmethyl sulfonylfluoride. The protein concentration
was measured with the BCA protein detection kit (Pierce) and ad-
justed for equal loading. For immunoprecipitation, lysates were in-
cubated with goat anti-mouse VEGFR-2 (R&D) for 1.5 hr at 4ºC
followed by incubation with fast-flow protein-G-Sepharose (Amer-
sham Biosciences), end over end, at 4ºC for 45 min. Proteins were
released by boiling in sample buffer (59 mM Tris-HCl [pH 6.8],
1.5% SDS, 4.35% glycerol, 4% b-mercaptoethanol, 0.0025% bro-
mophenol blue) and separated with SDS-PAGE. The following pri-
mary antibodies were used: mouse anti-phospho-tyrosine (4G10;
Cell Signaling), goat anti-mouse laminB, goat anti-mouse CD31,
and goat anti-actin (Santa Cruz Biotechnology). Immunoreactivity
was visualized by enhanced chemiluminescence. Quantification of
immunoreactive bands was made in Image Gauge (Fujifilm).
Supplemental Data
Supplemental Data include three figures and are available at http://
www.developmentalcell.com/cgi/content/full/10/5/625/DC1/.
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